GlassScriptPhysician profile
Hafsa Amjed
NPI 1104272798
$919.50
in general payments reported to CMS, 2019-2025
14 companies · $86.31 in 2025
The $86.31 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $151 · 2022: $356 · 2023: $295 · 2024: $30.67 · 2025: $86.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $412.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $265.46 | 2021-2023 | Jardiance |
| Dexcom, INC. | $244.52 | 2021-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $97.11 | 2021-2023 | Rybelsus, Ozempic |
| Abbvie INC. | $46.87 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.06 | 2023 | Jardiance, Tradjenta, Synjardy |
| Tandem Diabetes Care, INC. | $38.06 | 2022 | |
| Beta Bionics, INC. | $37.61 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amgen INC. | $34.32 | 2021-2025 | Evenity |
| Ascensia Diabetes Care US INC. | $29.11 | 2022 | |
| Insulet Corporation | $20.81 | 2025 | Omnipod |
| Antares Pharma, INC. | $19.22 | 2023 | Nocdurna, Tlando, Xyosted |
| Sanofi-Aventis U.S. LLC | $17.07 | 2022 | |
| Sequel Med Tech, LLC | $15.16 | 2025 | Twiist |
| Astrazeneca Pharmaceuticals LP | $15.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hafsa Amjed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.